Cancer
Researchers at Nazarbayev University have made a groundbreaking discovery in the field of cancer treatment, finding that carbon nanoparticles (CNPs) can induce DNA repair and drug resistance in cancer cells. This study, published in Cancer Nanotechnology, investigated the mechanisms by which CNPs interact with cancer cells and found that they
Cancer
Researchers from the University of Navarra have made a groundbreaking discovery in the field of cancer gene therapy, linking leishmaniasis to malignancy and drug resistance in mammalian cells. The team, led by Esther Larrea, found that the BRCT domain from the homologue of the oncogene PES1 in Leishmania major (LmjPES)
Cancer
Researchers from the University of Tokyo have made significant breakthroughs in understanding the role of histone methyltransferase SET domain-containing protein 8 (SETD8) in endometrial cancer. Their study uncovered the involvement of SETD8 in the proliferation of endometrial cancer cells and identified the downstream genes regulated by SETD8 via H4K20 methylation
Cancer
NYU Langone Health researchers have developed a novel biotechnology approach that combines targeted and immune therapies to attack cancer cells that have developed resistance to treatment. The technology, called HapImmune, uses a strategy that leverages the body's natural immune surveillance system to recognize and destroy cancer cells that
Cancer
A team of researchers from Perlmutter Cancer Center at NYU Langone Health has devised a novel strategy to enhance the effectiveness of targeted therapies, which are commonly used to treat cancer. By combining these therapies with immunotherapies, the team has developed a platform that can detect cancer-causing proteins and recruit
Cancer
Research conducted by a team from the University of Copenhagen has shed light on the potential of liquid biopsy in monitoring treatment response and early detection of treatment failure in advanced non-small cell lung cancer (NSCLC) patients. The study aimed to investigate the clinical validity of circulating tumor DNA (ctDNA)
Cancer
Research conducted at the University of Minnesota revealed that only 60% of patients undergoing cancer treatment and/or hematopoietic stem cell transplant received the human papillomavirus (HPV) vaccine, despite being at increased risk for developing a secondary HPV-associated malignancy. The study, published in Preventive Medicine Reports, aimed to determine HPV
Cancer
A comprehensive market analysis on the US Non-Small Cell Lung Cancer market has been published, providing insights into the pipeline products, epidemiology, market valuations, and forecast, as well as drugs sales and competitive landscape. The report offers a detailed examination of the Non-Small Cell Lung Cancer market, including treatment options,
Cancer
Researchers at AHEPA University Hospital in Greece have reported promising results in using immunotherapy as a treatment for non-small cell lung cancer in inoperable patients. According to the study, programmed death-ligand 1 (PD-L1) is a valuable marker for the success of immunotherapy, and patients with a higher PD-L1 score are
Cancer
Researchers have been working on developing innovative treatments for p53 mutant cancers, a type of cancer characterized by mutations in the tumor suppressor gene TP53. A new patent application, filed by Scott E. Millman, Lydia Finley, Scott Lowe, and John P. Morris IV, proposes using OGDH inhibitors to treat or
Cancer
Researchers at Universal Diagnostics have successfully demonstrated the use of microbiome signatures in plasma to aid in the early detection of colorectal cancer. Building on the company's previous findings, which revealed the potential of cell-free circulating tumor DNA (ctDNA) methylation, mutation, and fragmentation patterns for early-stage colorectal cancer
Cancer
Researchers at the Faculty of Medicine and University Hospital Cologne in Germany have made a groundbreaking discovery in the treatment of non-small cell lung cancer (NSCLC). According to a recent study published in the journal Cancers, EGFR inhibition by erlotinib has been shown to strongly modulate the tumor immune microenvironment
